BEVERLY, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX), a clinical stage
biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory and antibiotic
applications, provides additional details for upcoming investor and shareholder presentations.
On the morning of April 20, 2017, at 11AM Eastern (EDT), a pre-recorded presentation, audio and corresponding slide
deck, with particular emphasis given to Brilacidin interim trial results in Inflammatory Bowel Disease and Oral Mucositis, will be
made available at the Events and Presentation section of the company’s website: http://www.cellceutix.com/new-events-and-presentations/
Additionally, the Company is fielding investor and shareholder questions in advance of a live conference call,
scheduled for June 8, 2017 at 11AM EDT, as follow-up to the next quarterly report (10-Q) to be released in May. Questions for
the June call may be submitted in advance by emailing conference@cellceutix.com to be received by June 1, 2017. Dial-in instructions for participants will be announced one
week prior.
Alerts
Sign-up for Cellceutix email alerts at: http://www.cellceutix.com/email-alerts
About Cellceutix
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol “CTIX”.
Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes
it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while
actively seeking strategic partnerships. Cellceutix’s psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix
recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction.
Cellceutix’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber
Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory,
Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in
controlling cell mutations. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of
severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix is in a Phase 2 clinical trial with its novel
compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer; interim results have shown a
marked reduction in the incidence of severe oral mucositis (WHO Grade ≥ 3). Cellceutix’s lead antibiotic, Brilacidin, has completed
a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of
Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the
potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label
Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin
for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). Cellceutix has
formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson
Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix
web site at www.cellceutix.com.
Forward-Looking Statements: This press release contains forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning
projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements
regarding future product developments, including with respect to specific indications, and any other statements which are other
than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause Cellceutix’s
actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking
statements. Cellceutix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,”
“hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among
other factors that could cause actual results to differ materially from those expressed in forward-looking statements are
Cellceutix’s need for, and the availability of, substantial capital in the future to fund its operations and research and
development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix’s
compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed
in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix’s filings with the
Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no
obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect
events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as
required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT Cellceutix Corporation Leo Ehrlich info@cellceutix.com
